These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23411358)

  • 21. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
    Hoffmann L; Ramos JA; Souza EV; Araújo Ramos AL; Villela-Nogueira CA; Urményi TP; Tanuri A; Rondinelli E; Silva R
    Virol J; 2013 Feb; 10():57. PubMed ID: 23409973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
    Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
    Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
    Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
    J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
    Marks KM; Jacobson IM
    Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients.
    Khan HU; Khan S; Shah MA; Attaullah S; Malik MA
    PLoS One; 2020; 15(4):e0231480. PubMed ID: 32275694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.
    Abdel-Hameed EA; Rouster SD; Ji H; Ulm A; Hetta HF; Anwar N; Sherman KE; Shata MT
    Viral Immunol; 2016 May; 29(4):252-8. PubMed ID: 26885675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
    Sølund C; Krarup H; Ramirez S; Thielsen P; Røge BT; Lunding S; Barfod TS; Madsen LG; Tarp B; Christensen PB; Gerstoft J; Laursen AL; Bukh J; Weis N;
    PLoS One; 2014; 9(12):e113034. PubMed ID: 25438153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients.
    Zabek P; Opoka-Kegler J; Baka M; Dyda T; Stańczak GP; Stańczak JJ
    Przegl Epidemiol; 2013; 67(3):411-3, 521-3. PubMed ID: 24340552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C.
    Sargin Altunok E; Sayan M; Akhan S; Aygen B; Yildiz O; Tekin Koruk S; Mistik R; Demirturk N; Ural O; Kose Ş; Aynioglu A; Korkmaz F; Ersoz G; Tuna N; Ayaz C; Karakecili F; Keten D; Inan D; Yazici S; Koculu S; Yildirmak T
    Int J Infect Dis; 2016 Sep; 50():1-5. PubMed ID: 27401586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
    Irving WL; Rupp D; McClure CP; Than LM; Titman A; Ball JK; Steinmann E; Bartenschlager R; Pietschmann T; Brown RJ
    Antiviral Res; 2014 Oct; 110():52-9. PubMed ID: 25057759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba.
    Andonov A; Kadkhoda K; Osiowy C; Kaita K
    Can J Gastroenterol; 2013 Jul; 27(7):414-6. PubMed ID: 23862174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
    Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to anti-HCV protease inhibitors.
    Thompson AJ; Locarnini SA; Beard MR
    Curr Opin Virol; 2011 Dec; 1(6):599-606. PubMed ID: 22440917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
    Lim SR; Qin X; Susser S; Nicholas JB; Lange C; Herrmann E; Hong J; Arfsten A; Hooi L; Bradford W; Nájera I; Smith P; Zeuzem S; Kossen K; Sarrazin C; Seiwert SD
    Antimicrob Agents Chemother; 2012 Jan; 56(1):271-9. PubMed ID: 22064535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.
    Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V
    Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.
    Di Maio VC; Cento V; Di Paolo D; Aragri M; De Leonardis F; Tontodonati M; Micheli V; Bellocchi MC; Antonucci FP; Bertoli A; Lenci I; Milana M; Gianserra L; Melis M; Di Biagio A; Sarrecchia C; Sarmati L; Landonio S; Francioso S; Lambiase L; Nicolini LA; Marenco S; Nosotti L; Giannelli V; Siciliano M; Romagnoli D; Pellicelli A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Taliani G; Mastroianni C; Vespasiani-Gentilucci U; Romano M; Morisco F; Gasbarrini A; Vullo V; Bruno S; Baiguera C; Pasquazzi C; Tisone G; Picciotto A; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F;
    J Antimicrob Chemother; 2016 Mar; 71(3):739-50. PubMed ID: 26679249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.